Multicentre Trial of Suboxone in Opiate-dependent Subjects in Taiwan

Phase 4

Completed

• Conditions: Opiate Dependence
• Interventions: Drug: Buprenorphine + naloxone (Suboxone)

• Registration Number: NCT00901875
• Lead Sponsor: Indivior Inc.

Brief Summary

To determine whether Suboxone can be effectively used to treat Taiwanese ethnic subjects with opiate dependence.

Detailed Description

Not available

Study Timeline

• Study Start: 2009-03
• Study First Submitted: 2009-05-13
• Study First Submitted QC: 2009-05-13
• Study First Posted: 2009-05-14
• Primary Completion: 2009-11
• Status Verified: 2010-01
• Study Completion: 2010-01
• Last Update Submitted: 2012-11-28
• Last Update Posted: 2012-11-30

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 127

Inclusion Criteria

• Male or female subjects, 20 years of age or older at screening visit.
• Subjects must meet DSM-IV/COWS1,2 criteria for opiate dependence. (COWS total score ≥5)
• Subjects must have a positive urine drug screen (dipstick test) for an opiate or morphine at study entry
• Subject is seeking treatment with the desire to discontinue opiate use as an initial goal but willing to consider and accept longer treatment if necessary.
• Subject is in good physical health or, if he/she has a medical condition needing ongoing treatment, must be in the care of a physician who is willing to take responsibility for such treatment and work with the study physician. Study physicians able to manage the subject for his/her general medical condition, may be assigned this role. These same conditions apply in case of subjects with psychiatric disorder(s) needing ongoing treatment.
• Subject is agreeable to and capable of signing informed consent form.
• Females of childbearing potential must have a negative pregnancy test and agree to use a double barrier method or condoms/diaphragm and spermicide contraceptive method during the study.

Read More

Exclusion Criteria

• Women who are pregnant, lactating or breast feeding.
• Subjects have any acute medical condition that would make participation, in the opinion of the treating physician or the principal investigator, medically hazardous (e.g., acute hepatitis, unstable cardiovascular, liver or renal disease).
• Subjects have clinically significant liver disease.
• Subjects who have demonstrated a previous hypersensitivity to buprenorphine or naloxone.
• Subjects who are considered an immediate risk for suicide, are acutely psychotic, severely depressed, or in need of inpatient treatment.
• Subjects who are dependent on alcohol, benzodiazepines or other drugs of abuse (except tobacco) to the point of requiring immediate medical attention.
• Subjects received methadone treatment within the last 30 days since screening visit.
• Subjects have any pending legal action that could prohibit continued participation.
• Subjects have participated in other clinical studies within the past 30 days.
• Subjects who are expecting to leave the clinic geographic area prior to study completion.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Suboxone, maximum 8mg	Buprenorphine + naloxone (Suboxone)	-
Buprenorphine + naloxone	Buprenorphine + naloxone (Suboxone)	-
Buprenorphine + naloxone (Suboxone)	Buprenorphine + naloxone (Suboxone)	-

Primary Outcome Measures

Name	Time	Method
Retention in treatment	weekly up to 13 weeks

Trial Locations

Locations (8)

Chang-Gung Memorial Hospital, Linkou Branch; 🇨🇳 Gueishan, Taiwan

Chang-Gung Memorial Hospital, Keelung Branch; 🇨🇳 Keelung, Taiwan

BALI Psychiatric Center; 🇨🇳 Taipei, Taiwan

Jianan Mental Hospital; 🇨🇳 Ren-De, Tainan County, Taiwan

Taoyuan Mental Hospital; 🇨🇳 Taoyuan City, Taoyuan County, Taiwan

Taipei City Hospital - Song De Branch; 🇨🇳 Taipei, Taiwan

China Medical University Hospital; 🇨🇳 Taichung, Taiwan

Taipei Veterans General Hospital; 🇨🇳 Taipei, Taiwan